Parsabiv is intended to treat secondary hyperhythroidism in patients with chronic kidney disease who are undergoing dialysis. The drug should be administered intravenously three times at week at the end of a patient’s dialysis session, according to the report.
The drug, known by the generic name etelcalcetide, is the first new therapy approved for the disease in 12 years, according to Thousand Oaks, Calif.-based Amgen.
Analysts expect annual sales of the drug to exceed $600 million by 2023.
More articles on supply chain:
GHX names 50 best healthcare supply chains in North America
10 statistics on drug, device recalls in Q4
Why UPS drivers don’t turn left
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
